In this chapter, we will review some methods and platforms related to the
diagnosis of Alzheimer’s disease (AD). The global prevalence of dementia and AD
shows the urgent requirement of effective treatment, where an accurate and early
diagnosis plays an important role. Apart from cognitive diagnosis that clarifies the
cognitive deterioration of AD, abundant clinical studies have consistently recognised
the core neuropathological features and related fluid biomarkers as utile indicators for
the diagnosis and prognosis of AD and its preclinical stages. In order to enhance the
accuracy of detecting these biomarkers, convinced methods and platforms are essential.
Here, we summarised associated platforms, including imaging platforms (e.g., positron
emission tomography (PET) and structural imaging), enzyme-linked immunosorbent
assays (ELISA), and matrix-assisted laser desorption/ionisation – time of flight – mass
spectrometry (MALDI-TOF-MS).
Keywords: Amyloid-β (Aβ), Alzheimer’s Disease, Biomedical Modelling,
Biomarker, Cerebroporomehcaincs, Dementia, Enzyme-linked Immunosorbent
Assays (ELISA), Matrix-Assisted Laser Desorption/Ionisation – Time of Flight –
Mass Spectrometry (MALDI-TOF-MS), MultipleNetwork Poroelastic Theory
(MPET), Tau, Neuroimaging, Virtual Physiological Human (VPH).
